Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2160 • ACR Convergence 2023
Poly-Refractory Rheumatoid Arthritis: All B/tsDMARD Classes Exhausted – An Uncommon Disease Subset with Distinct Inflammatory and Non-inflammatory Phenotypes
Paula David¹, Andrea Di Matteo¹, Or Hen¹, Shouvik Dass², Helena Marzo-Ortega³, Paul Emery⁴, Benazir Saleem² and Dennis McGonagle⁵, ¹University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Leeds, United Kingdom, ²Leeds Teaching Hospitals NHS Trust, Rheumatology, Chapel Allerton Hospital, Leeds, United Kingdom, ³NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: We previously reported on difficult to treat Rheumatoid Arthritis (RA) in nearly 1600 patients treated with biologic (b) or target synthetic (ts) DMARDs including…
Abstract Number: 2426 • ACR Convergence 2023
The Role of β-catenin in Synovial Lining Fibroblast Differentiation
Sonia Presti¹, Gerald F.M. Watts¹, Junning Case¹, Zhu Zhu², Teri Bowman¹, Hung Nguyen¹, Gabriel Nigrovic¹, Ce Gao¹, Kartik Bhamidipati¹, Yuhong Li¹, Suppawat Kongthong¹, Fan Zhang³, Anna Helena Jonsson¹, Accelerating Medicines Partnership Program (AMP RA/SLE) Network⁴, STARS BWH¹, Michael Brenner⁵, Shideh Kazerounian¹ and Kevin Wei⁵, ¹Brigham and Women's Hospital, Boston, MA, ²10x Genomics, St. Louis, MO, ³University of Colorado, Aurora, CO, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: In healthy synovium, lining fibroblasts promote joint health by secreting proteoglycans that lubricate the joint cavity. In rheumatoid arthritis (RA), sublining fibroblasts undergo marked…
Abstract Number: 2481 • ACR Convergence 2023
Pre-pregnancy Gene Expression Signatures Among Women with Rheumatoid Arthritis May Represent Predictive Biomarkers for Subsequent Improvement or Worsening During Pregnancy
Matthew Wright¹, Mette Smed², Lee Nelson³, Jørn Olsen⁴, Merete Hetland⁵, Nicholas Jewell⁶, Vibeke Zoffmann² and Damini Jawaheer¹, ¹Northwestern University, Chicago, IL, ²Juliane Marie Centre, Rigshospitalet, Copenhagen, Denmark, ³Fred Hutchinson Cancer Center, Seattle, WA, ⁴Aarhus University Hospital, Aarhus, Denmark, ⁵Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁶London School of Hygiene and Tropical Medicine, London, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) can improve naturally during pregnancy in a substantial proportion of women (50-75%), while it may worsen or remain unchanged in others.…
Abstract Number: 2582 • ACR Convergence 2023
Expansion of Circulating HLA-DR+ Peripheral Helper T Cells and CXCR5−CD38+ Mature Naïve B Cells in ACPA-positive Individuals At-risk for and with Classified RA
Hideto Takada¹, Kristen Demoruelle¹, Kevin Deane¹, Shohei Nakamura², Yasuhiro Katsumata³, Katsunori Ikari², Jane Buckner⁴, William H. Robinson⁵, Jennifer Seifert¹, Marie Feser¹, LauraKay Moss¹, Jill Norri⁶, Masayoshi Harigai³, Elena Hsieh¹, Michael Holer¹ and Yuko Okamoto², ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Stanford University, Palo Alto, CA, ⁶Colorado School of Public Health, Denver, CO

Background/Purpose: Production of ACPA following T and B cell interactions is a hallmark of ACPA+ RA. Recently identified peripheral helper T (Tph) cells have B…
Abstract Number: 0062 • ACR Convergence 2023
Differential Metabolic Profiles, Activation and Circadian Dynamics in Rheumatoid Arthritis and Psoriatic Arthritis Circulatory Monocytes
Alyssa Gilmore¹, Success Amaechi², Megan Hanlon³, Dumitru Anton⁴, Carl Orr⁵, Viviana Marzaioli⁶, Douglas Veale⁷ and Ursula Fearon¹, ¹Trinity College Dublin, Dublin, Ireland, ²Trinity College Dublin, Mullingar, Ireland, ³Molecular Rheumatology, Dublin, Ireland, ⁴Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁵Saint Vincent's University Hospital, Dublin, Ireland, ⁶Trinity College Dublin and University College Dublin, Dublin, Ireland, ⁷St.Vincent's University Hosp, Dublin, Ireland
Background/Purpose: While Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) share many features, they are distinct in clinical presentation and molecular profile. As monocytes are crucial…
Abstract Number: 0163 • ACR Convergence 2023
Uncovering Discrepancies: Analysis of Glucocorticoid Exposure Among Patients with Rheumatoid Arthritis in Electronic Health Record Data versus Medicare Claims
Jing Li¹, Julia Kay¹, Sharon Abada¹, Andriko Palmowski², Rachael Stovall¹, Jinoos Yazdany³ and Gabriela Schmajuk⁴, ¹University of California San Francisco, San Francisco, CA, ²Charité - Universitätsmedizin Berlin, Berlin, Germany, ³University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA
Background/Purpose: Understanding glucocorticoid (GC) exposure is critical for observational analyses in rheumatology. However, obtaining an accurate measure of GC exposure, including dosage and duration, has…
Abstract Number: 0338 • ACR Convergence 2023
Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis or Ankylosing Spondylitis: Data from COVAD Patient-reported E-survey
Diego Benavent¹, Marco Fornaro², Florenzo Iannone³, Lorenzo Cavagna⁴, Masataka Kuwana⁵, Naveen R⁶, Vishwesh Agarwal⁷, Jessica Day⁸, Mrudula Joshi⁹, Sreoshy Saha¹⁰, Kshitij Jagtap¹¹, Wanruchada Katchamart¹², Phonpen Akarawatcharangura Goo¹³, Binit Vaidya¹⁴, Tsvetelina Velikova¹⁵, Parikshit Sen¹⁶, Samuel Shinjo¹⁷, Ai Lyn Tan¹⁸, Nelly Ziade¹⁹, Marcin Milchert²⁰, Abraham Edgar Gracia-Ramos²¹, Carlo Caballero²², Hector Chinoy²³, Vikas Agarwal⁶, Rohit Aggarwal²⁴, Latika Gupta²⁵ and Vincenzo Venerito²⁶, ¹Hospital la Paz, Madrid, Spain, ²University of Bari, Grottaglie, Italy, ³Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ⁴Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁵Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁶Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁷Mahatma Gandhi Missions Medical College, Lucknow, India, ⁸Walter and Eliza Hall Institute, Melbourne, Australia, ⁹Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ¹⁰Mymensingh Medical College, Faridpur, Bangladesh, ¹¹Seth Gordhandhas Sunderdas Medical College and King Edwards Memorial Hospital, Mumbai, India, ¹²Mahidol University, Bangkok, Thailand, ¹³Department of Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand, ¹⁴National Center for Rheumatic Diseases (NCRD), Ratopul, Kathmandu, Nepal., Kathmandu, India, ¹⁵Department of Clinical Immunology, Medical Faculty, University Hospital "Lozenetz", Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹⁶Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, ¹⁷Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, Brazil, ¹⁸University of Leeds, Leeds, United Kingdom, ¹⁹Saint-Joseph University, Beirut, Lebanon, ²⁰Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, ²¹Department of Internal Medicine, General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P. 02990, Mexico City, Mexico, ²²Universidad del Norte, Barranquilla, Colombia, ²³The University of Manchester, Sale, United Kingdom, ²⁴University of Pittsburgh, Pittsburgh, PA, ²⁵Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom, ²⁶Rheumatology Department, Università degli Studi di Bari, Bari, Italy
Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA), including either Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS), are some of the most commonly diagnosed autoimmune rheumatic…
Abstract Number: 0393 • ACR Convergence 2023
Pulmonary Involvement in Patients with Seropositive and ACPA Positive Rheumatoid Arthritis (RA-ILD) – Novel Screening Protocol for Early Detection of Pulmonary Involvement
Florian Popp¹, Martin Hoffmann², Johannes von Kempis³, Martin Welcker¹, Werner von Wulffen² and Frank Reichenberger², ¹Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ²Augustinum Klinik München, Department of pneumology, Munich, Germany, ³Kantonsspital St. Gallen, Division of rheumatology and immunology, St. Gallen, Switzerland
Background/Purpose: Seropositive and ACPA positive Rheumatoid Arthritis (RA) is associated with significant cardiovascular and pulmonary comorbidity. However, screening for early detection of pulmonary involvement especially…
Abstract Number: 0410 • ACR Convergence 2023
Usefulness of RAPID3 in Assessing Unmet Needs of Patients with Rheumatoid Arthritis in Remission or with Low Disease Activity　-a Multicenter Observational Study: T-FLAG Study-
Mochihito Suzuki¹, Nobunori Takahashi², Yasumori Sobue³, yoshifumi Ohashi¹, Ryo Sato¹, Masataka Maeda¹, Hironobu Kosugiyama¹, yusuke Ohno¹, kenya terabe⁴, Shuji Asai¹ and Shiro Imagama¹, ¹Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Department of Orthopedic Surgery, Aichi Medical University, Nagakute, Japan, ³Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan, ⁴Nagoya University, Nagoya, Japan
Background/Purpose: Routine Assessment of Patient Index Data 3 (RAPID3) is a patient-reported outcome (PRO) that can be used to assess the condition of rheumatoid arthritis…
Abstract Number: 0427 • ACR Convergence 2023
Molecular Characterization of Biologic and Targeted Synthetic DMARDs Effects Through Ex- vivo Studies in Rheumatoid Arthritis Immune Cells
Laura Muñoz-Barrera¹, Carlos Perez-Sanchez², Laura Romero-Zurita¹, Rafaela Ortega Castro³, Jerusalem Calvo⁴, Pilar Font Ugalde¹, Marta Rojas⁵, Ismael Sanchez-Pareja¹, Maria del Carmen Abalos-Aguilera⁶, Desiree Ruiz-Vilchez¹, Christian Merlo-Ruiz¹, Mª Angeles Aguirre⁷, Nuria Barbarroja⁸, Tomás Cerdó¹, Eduardo Collantes Estévez⁹, Marta Alarcon-Riquelme¹⁰, Alejandro Escudero Contreras⁴ and Chary Lopez-Pedrera¹¹, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ²IMIBIC, Córdoba, Spain, ³Hospital Reina Sofía, Cordoba, Spain, ⁴Reina Sofia University Hospital, Córdoba, Spain, ⁵Hospital Universitario Reina Sofía, Cordoba, Spain, ⁶Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁷Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁸University of Cordoba, Córdoba, Spain, ⁹Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, ¹⁰Center for Genomics and Oncological Research (GENYO), Granada, Spain, ¹¹IMIBIC - Reina Sofia Hospital, Córdoba, Spain
Background/Purpose: Despite advances in rheumatoid arthritis (RA) treatment, a significant proportion of patients (10-30%) fail to respond to current medications, including biologics. A better characterization…
Abstract Number: 0444 • ACR Convergence 2023
Safety, Tolerability, and Pharmacokinetics of a Novel Synthetic Disease Modifying Antirheumatic Drug, TCK-276, After Single Ascending Dose in Healthy Subjects and Multiple Ascending Doses in Patients with Rheumatoid Arthritis
Chie Watai¹, Kazuoki Tsuruda², Yoshinori Tsumura¹ and Daisuke Tasaki¹, ¹Teijin Pharma Limited, Chiyoda City Tokyo, Japan, ²Teijin America, Inc., Sausalito, CA
Background/Purpose: TCK-276 is a highly potent, orally active, and selective cyclin dependent kinase 4/6 (CDK4/6) inhibitor that is in development as a novel synthetic disease…
Abstract Number: 0466 • ACR Convergence 2023
Impact of Postpartum on Patients with Inflammatory Rheumatic Diseases: The P2Rheum Study
Marie Hornez¹, Anna Molto², Maxime Leroy³, beatrice banneville⁴, Rakiba Belkhir⁵, elodie chauvet⁶, Marion Couderc⁷, Emanuelle Dernis⁸, sandra Desouches⁹, Valerie Devauchelle¹⁰, Aline Frazier-Mironer¹¹, Laure Gossec¹², elisabeth Gervais¹³, Hubert Marotte¹⁴, Christophe Richez¹⁵, Jeremie SELLAM¹⁶, Raphaele Seror¹⁷, Véronique Le Guern¹⁸, Gaelle Guettrot-Imbert¹⁸, Nathalie Costedoat-Chalumeau¹⁹, Rene-Marc Flipo²⁰ and Jean-Guillaume Letarouilly²¹, ¹University of Lille, Lille, France, ²HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ³CHU Lille - Department of Biostatistics, Lille, France, ⁴Sorbonne universite and Pitié Salpêtrière Hospital, la Garenne Colombes, France, ⁵Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, France, ⁶CH Perpignan, Perpignan, France, ⁷CHU Gabriel Montpied, Clermont Ferrand, France, ⁸CH Le Mans, Le Mans, France, ⁹Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris, Paris, France, ¹⁰UBO, Brest, France, ¹¹APHP Lariboisiere Hospital, Paris, France, ¹²Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ¹³CHU Poitiers, Poitiers, France, ¹⁴CHU Saint-Etienne, Saint-Etienne, France, ¹⁵Université de Bordeaux, Bordeaux, France, ¹⁶Sorbonne Université APHP, Paris, France, ¹⁷University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ¹⁸APHP Hôpital Cochin, Paris, France, ¹⁹Inserm DR Paris 5, Paris, France, ²⁰La Lettre du Rhumatologue, Paris, France, ²¹CHU Lille, Lille, France
Background/Purpose: There are limited data on the impact of the postpartum period (PP) on the activity of inflammatory rheumatic disorders (IRD), and the data available…
Abstract Number: 0754 • ACR Convergence 2023
Towards a Guide for Evidence-based Remote Monitoring: Sensitivity of Patient Reported Outcomes to Change in Disease Activity Status in Early and Established Rheumatoid Arthritis
Agnes Loiojen¹, Elise van Mulligen², Annette van der Helm-van Mil³ and Pascal de Jong², ¹Erasmus Medical Center, department of rheumatology, Rotterdam, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the treatment and follow-up of rheumatoid arthritis (RA) patients, it has become more desirable to detect changes in disease activity through remote monitoring.…
Abstract Number: 0807 • ACR Convergence 2023
Inferring Disease Activity Scores and Low Disease Activity at Registry Visits Based on Structured and Narrative Data from Electronic Health Records
David Cheng¹, Dana Weisenfeld², Kumar Dahal², Qing Liu², Vidul Ayakulangara Panickan³, Mary Jeffway², Thany Seyok², Gregory McDermott², Michael Weinblatt⁴, Nancy Shadick⁵, Tianxi Cai⁶ and Katherine Liao², ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴Harvard Medical School, Waban, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Real-world data including electronic health records (EHRs) are a promising resource for learning to optimize treatment strategies for rheumatoid arthritis (RA). A major challenge…
Abstract Number: 0974 • ACR Convergence 2023
Validation of Boolean 2.0 Criteria for Assessing Remission and Predicting Quality of Life in Korean Patients with Rheumatoid Arthritis Undergoing Targeted Therapy
Soo-Kyung Cho¹, Yeo-Jin Song¹, Jungyong Han², Hye Won Kim³, Eunwoo Nam³ and Yoon-Kyoung Sung¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Hanyang University Institute for Rheumatology Research, Seoul, South Korea
Background/Purpose: The management of rheumatoid arthritis (RA) focuses on achieving remission as a treatment goal. The updated ACR/EULAR remission definition (Boolean criteria 2.0) has raised…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].